Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome.
VectivBio AG · Short Bowel Syndrome
Phase 3
Active, not recruiting
158
2025-07
Industry sponsor intelligence
VectivBio AGClinical Pipeline.
Lead-sponsor view of VectivBio AG's indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 8
- Recruiting
- 0
- Active
- 1
- Completed
- 6
- Results posted
- 4
- Avg enrollment
- 59
Pipeline overview
Programs by phase and activity.
Velocity
VectivBio AG trials by start year
Study start year · indexed snapshot
Development
Trials by phase
8phase labels
Early Phase 10
Phase 14
Phase 22
Phase 32
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Apraglutide → | 8 | 4 | 2 | 2 | 0 | 1 |
Active peptide trials
In motion now.
NCT IDStudyPhase / statusEnrollmentUpdated
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
A Phase 1 Open-Label Evaluation of the Pharmacokinetics and Safety of a Single Dose of Apraglutide in Subjects With Normal and Impaired Hepatic Function
VectivBio AG · Hepatic Impairment
Phase 1
Completed
16
2025-07
Metabolic Balance Study of Apraglutide in Patients With Short Bowel Syndrome, Intestinal Failure (SBS-IF) and Colon-in-Continuity (CIC)
VectivBio AG · Short Bowel Syndrome
Phase 2
Completed
10
2025-06
Trial to Evaluate Efficacy and Safety of Apraglutide in SBS-IF
VectivBio AG · Short Bowel Syndrome
Phase 3
Completed
164
2024-11
Study of Pharmacokinetics and Safety of Apraglutide in Participants With Normal and Impaired Kidney Function.
VectivBio AG · Chronic Kidney Disease
Phase 1
Completed
16
2024-10
Relative Bioavailability of a New Presentation of Apraglutide Versus the Reference Formulation
VectivBio AG · Healthy Subjects
Phase 1
Completed
34
2024-10
Evaluation of Apraglutide on Gastric Emptying
VectivBio AG · Healthy Subjects
Phase 1
Completed
42
2024-10
Search sponsor records
All VectivBio AG studies.
This page groups studies where VectivBio AG is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
8 matching studies
Last registry update first
Recent updates
Latest registry movement.
NCT05415410Proof-of-concept Trial of Apraglutide in Acute Graft Versus Host Disease (aGVHD)Oct 20, 2025NCT05706623A Phase 1 Open-Label Evaluation of the Pharmacokinetics and Safety of a Single Dose of Apraglutide in Subjects With Normal and Impaired Hepatic FunctionJul 10, 2025NCT05018286Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome.Jul 2, 2025NCT04964986Metabolic Balance Study of Apraglutide in Patients With Short Bowel Syndrome, Intestinal Failure (SBS-IF) and Colon-in-Continuity (CIC)Jun 18, 2025NCT04627025Trial to Evaluate Efficacy and Safety of Apraglutide in SBS-IFNov 27, 2024NCT04699032Study of Pharmacokinetics and Safety of Apraglutide in Participants With Normal and Impaired Kidney Function.Oct 26, 2024NCT06002555Relative Bioavailability of a New Presentation of Apraglutide Versus the Reference FormulationOct 26, 2024NCT05995704Evaluation of Apraglutide on Gastric EmptyingOct 24, 2024